MD Biosciences and Becton Dickinson sign Agreement For the
Distribution of Streptococcus Cell Wall Extract, PG-PS.
Released on = April 7, 2005, 9:07 pm
Press Release Author = Amy Clausen
Industry = Biotech
Press Release Summary = MD Biosciences announces today that it has entered into an
agreement with BD Lee Laboratories to sell PG-PS (peptidoglycan-polysaccharide
polymer streptococcus cell wall extract) products for induction of inflammatory
response in in vivo models of disease.
Press Release Body = St. Paul, MN, April 08, 2005 – MD Biosciences, an international
provider of inflammatory research products and pre-clinical services, announces
today that it has entered into an agreement with BD (Becton Dickinson and Company)
Lee Laboratories to sell PG-PS (peptidoglycan-polysaccharide polymer streptococcus cell wall extract) products. BD Lee Laboratories approached MD Biosciences for its
established leadership in inflammations research and the agreement will serve to
expand and strengthen MD Biosciences inflammatory research product line.
PG-PS is purified polymers produced from the cell walls of Streptococcus pyogenes
Group A. The use of these polymers in in vivo models of disease induces an acute and
chronic inflammatory reaction, which can evolve into a remittent, arthritic response
that is representative of naturally caused inflammatory disorders. “The addition of
PG-PS will complement our focused product line of inflammatory research reagents and
will provide an additional resource for clients who are engaged in in vivo models of
disease for their drug discovery efforts” commented Amy Clausen, Marketing Manager
for MD Biosciences.
PG-PS is a valuable resource to researchers involved in inflammatory drug discovery.
The induction of a biphasic inflammatory response in disease models is used for the
evaluations and studies of anti-inflammatory drugs and therapies for inflammatory
diseases such as arthritis, granulomatous enterocolitis (resembling Crohn’s
disease), and others.
About MD Biosciences
MD Biosciences (www.mdbiosciences.com) is an international biotech company providing
the most advanced products and pre-clinical services for pharmaceutical and
biotechnology companies engaged in inflammations research. With specialized
laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally
recognized experts provides in-depth expertise and technologies to tackle problems
and provide total solutions to the inflammatory disease drug discovery market.
About BD Lee Laboratories
Lee Laboratories, a fully owned subsidiary of BD (Becton Dickinson), offers reagents
and services for diagnostics and inflammation research. BD is a medical technology
company that serves life science researchers, clinical laboratories, and the
healthcare industry.
--------
The information in this press release should be considered accurate only as of the
date of the release. MDB has no intention of updating and specifically disclaims any
duty to update the information in these press releases.
Web Site = http://www.mdbiosciences.com
Contact Details = MD Biosciences
1000 Westgate Dr
St Paul, MN 55114
651-641-1770
651-641-1773 (fax)
info-us@mdbiosciences.com
Printer
Friendly Format
Back to previous
page...
Back to home page...
Submit your
press releases...
|